Releases - Vitrolife AB (publ)

View:
 

Found press releases

 

Vitrolife named as winner of the 2012 SwedenBIO Award

5/24/2012 11:30 AM EST
Vitrolife has been named as the winner of the 2012 SwedenBIO Award. The prize is awarded by SwedenBIO, which is an association of member companies with the aim of promoting growth in the Life Science industry in Sweden. State Secretary Håkan Ekengren today awarded the distinction to Vitrolife at SwedenBIO’s Annual Meeting.
The jury’s statement was as follows: “Through its innovative products and focus on the...

Report from Annual General Meeting of Vitrolife AB (publ)

4/20/2012 2:30 AM EST
At Vitrolife’s Annual General Meeting yesterday, April 19, the following, amongst other things, was decided:

· The Board’s proposed dividend of SEK 0.60 per share for the financial year 2011 was approved. Tuesday April 24, 2012 was adopted as the record day.

· Re-election of Board members Patrik Tigerschiöld, Fredrik Mattsson, Tord Lendau, Maris Hartmanis and Barbro Fridén and new election of Carsten Browall, in...

Interim report January-March 2012

4/19/2012 9:00 AM EST
Strong sales growth in Asia and strengthened operating income
First quarter in brief

· Sales growth was 11 percent in local currency. Sales were the highest ever for a single quarter and amounted to SEK 100 (88) million, corresponding to an increase of 13 percent in SEK. Fertility sales in Asia increased by 50 percent in local currency.

· Operating income (EBIT) amounted to SEK 15 (10) million,...

Thomas Axelsson appointed CEO of Vitrolife

4/18/2012 8:00 AM EST
Vitrolife’s Board has today appointed Thomas Axelsson as the new CEO of Vitrolife. Thomas has been working as the Acting CEO of the Group since November 2011.
Thomas Axelsson has broad experience and has displayed successful leadership and is the choice of the Board for the position of CEO after a thorough recruitment process where Thomas has competed with a number of other strong candidates. “Thomas has learnt...

All patients included in the clinical study on STEEN Solution™ in the USA

4/18/2012 2:30 AM EST
In the clinical study that was begun during 2011 on STEEN Solution™ with the aim of forming a basis for sales approval in the USA, a total of 13 patients have now received transplants. The required number of patients, which was 12, has thereby been included in the study. “Even if some work remains and it is difficult to assess how the FDA will reply it is now reasonable to assume that this is a big step closer to...

Conference call interim report

4/12/2012 5:00 AM EST
Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January-March 2012. The presentation will be held in English.
Time: Friday, April 20, 2012 at 10 a.m. CET.

Registration can preferably be done in advance under the following link:
https://eventreg1.conferencing.com/webportal3/reg.html?Acc=533433&Conf=183317
or shortly before the conference starts...

Annual report 2011

3/26/2012 5:00 AM EST
Today Vitrolife is publishing the Annual Report for 2011 in Swedish. The Annual Report is attached to this press release and will also be available on www.vitrolife.com.
The printed version of the Annual Report will be distributed by mail during the week commencing 2 April. It will be distributed to Nordic shareholders who are new from last year and to remaining shareholders who have requested that the annual...

Notice of Annual General Meeting of Vitrolife AB (publ)

3/19/2012 7:00 AM EST
The Annual General Meeting of Vitrolife AB (publ) will take place on Thursday April 19, 2012, at 5 p.m. in the company’s premises at Gustaf Werners gata 2 in Gothenburg. Notice of attendance at the Annual General Meeting shall be given no later than Friday, April 13, 2012, at 12 noon.
Shareholders wishing to participate at the Annual General Meeting shall notify the company by mail to Vitrolife AB (publ), Box...

Vitrolife preparing distribution of the transplantation business

3/19/2012 6:00 AM EST
Vitrolife AB (publ) is today publishing the decision of the Board to begin preparations for a spin-off of the transplantation business, which today is run in the subsidiary Xvivo Perfusion AB. The spin-off will take place through distribution of the shares in the subsidiary in accordance with “Lex Asea”. It is intended that the shares in Xvivo Perfusion AB will be listed on NASDAQ OMX First North in connection with...

Proposal of the Election Committee regarding members of the Board etc. for Vitro...

3/16/2012 6:00 AM EST
The Election Committee of Vitrolife, which was appointed in accordance with the resolution of the Annual General Meeting on April 27, 2011, consists of:

Henrik Blomquist, representing Bure Equity AB
Johan Ståhl, representing Lannebo Fonder
Martin Lewin, representing Eccenovo AB
Patrik Tigerschiöld, Chairman of the Board

The Election Committee proposes the following to the Annual General Meeting of Vitrolife that...

Vitrolife AB (publ)

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs....

View more


  CONTACT